SAR 408701

Drug Profile

SAR 408701

Alternative Names: Maytansin-loaded anti-CEACAM5 mAb; SAR408701

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ImmunoGen
  • Developer Sanofi
  • Class Cytostatics; Drug conjugates; Immunoconjugates
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 17 Oct 2017 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease, Second-line therapy or greater, Metastatic disease, In adults, In the elderly) in Japan (IV) (NCT03324113)
  • 17 Oct 2017 Phase-I clinical trials in Solid tumours (In the elderly, In adults, Late-stage disease, Metastatic disease, Monotherapy) in Japan (IV) (NCT03324113)
  • 30 May 2017 ImmunoGen and Sanofi amends a licensing agreement granting exclusive, fully-paid license of SAR 408701 to Sanofi
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top